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Abstract
Usual sleep duration is a heritable trait correlated with psychiatric morbidity, cardiometabolic 
disease and mortality, although little is known about the genetic variants influencing this trait. A 
genome-wide association study of usual sleep duration was conducted using 18 population-based 
cohorts totaling 47,180 individuals of European ancestry. Genome-wide significant association 
was identified at two loci. The strongest is located on chromosome 2, in an intergenic region 35–
80 kb upstream from the thyroid-specific transcription factor PAX8 (lowest p=1.1 ×10−9). This 
finding was replicated in an African-American sample of 4771 individuals (lowest p=9.3 × 10−4). 
The strongest combined association was at rs1823125 (p=1.5 × 10−10, minor allele frequency 0.26 
in the discovery sample, 0.12 in the replication sample), with each copy of the minor allele 
associated with a sleep duration 3.1 minutes longer per night. The alleles associated with longer 
sleep duration were associated in previous genome-wide association studies with a more favorable 
metabolic profile and a lower risk of attention deficit hyperactivity disorder. Understanding the 
mechanisms underlying these associations may help elucidate biological mechanisms influencing 
sleep duration and its association with psychiatric, metabolic and cardiovascular disease.
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INTRODUCTION
Usual sleep duration is an important determinant of daytime sleepiness; moreover, both 
short and long sleep duration have been consistently associated with psychiatric illness, 
hypertension, diabetes mellitus, coronary heart disease and mortality, although the 
mechanisms underlying these associations are poorly understood. Significant heritability of 
usual sleep duration has been reported from twin studies, with heritability estimates 
generally in the range of 0.40–0.55 [1–3]. A number of neurotransmitters and neuropeptides 
are known to regulate sleep-wake behavior, and genetic screens in non-mammalian 
vertebrates have demonstrated an important role of ion channels, which regulate neural 
activity (reviewed in [4]). Polymorphisms in the human period 2 (PER2) and casein kinase 
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1d (CSNK1D) genes, known elements of the circadian molecular clock, are associated with 
autosomal dominant advanced sleep phase syndrome in isolated pedigrees [5,6]. The genetic 
basis for heritability of usual sleep duration, however, remains largely unknown. Candidate 
gene studies have inconsistently implicated genes associated with the mammalian circadian 
clock, including BHLHE41 (DEC2) and CLOCK [7–9], and the glutamate receptor-encoding 
GRIA3 [10]. In a small genome-wide association study (GWAS) of usual sleep duration in 
749 Framingham Heart Study participants, no genome-wide significant associations were 
identified [11]. Recently, a GWAS in over 4000 individuals in seven European cohorts 
identified a polymorphism in ABCC9, encoding an ATP-sensitive potassium channel, that 
explained approximately 5% of the variance in usual sleep duration [12]. This finding was 
not replicated in other cohorts; however, knockdown of this gene in Drosophila results in 
lack of sleep during the first 3 hours of the night. To date, no replicated associations 
between common genetic variants and sleep duration (or other sleep parameters) have been 
reported from GWAS studies. In the present study, we utilize self-report data on usual sleep 
duration, collected by 18 community-based cohort studies that have genotyped their cohorts, 
in order to identify common genetic variants associated with sleep duration. This study 
comprises a community-based sample of 47 180 individuals, approximately 10-fold larger 
than all previously reported GWAS studies of this phenotype [11, 12], and is the first to 
show replication in an independent sample.
METHODS
Cohorts
Participating cohorts were prospective studies that had collected self-report data on usual 
sleep duration. The analysis was initiated by the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) [13], but was extended beyond that initial group in 
order to obtain sufficient power for the analysis. Eighteen cohorts were ultimately included 
in the discovery sample: the Atherosclerosis Risk in Communities (ARIC) Study [14], 
Cardiovascular Health Study (CHS) [15], Framingham Heart Study (FHS) [16–18], Health 
Aging and Body Composition (HABC) Study [19], Helsinki Birth Cohort Study (HBCS) 
[20], Invecchiare in Chianti (InCHIANTI) [21], Osteoporotic Fractures in Men (MrOS) 
Study [22, 23], Quebec Family Study (QFS) [24], Queensland Institute of Medical Research 
Twins Study (QIMR) [2], Rotterdam Study I and II (RSI and RSII) [25], Study of Health in 
Pomerania (SHIP) [26], Study of Osteoporotic Fractures (SOF) [27], TwinsUK [28], 
Wisconsin Sleep Cohort (WiSC) [29], Young Finns Study (YFS) [30], and genotyped 
subsets of the Health Professionals Follow-up Study (HPFS) [31] and the Nurses Health 
Study (NHS) [32]. As shown in Table 1, the discovery cohorts were located in Europe, 
Australia and North America. This analysis included only participants of European ancestry, 
as determined by self-report, with additional exclusion in some cohorts for failure to cluster 
with European samples in principal components analysis or multidimensional scaling 
(ARIC, HPFS, MrOS, NHS, RS I&2, SHIP, SOF, TwinsUK, WiSC). Replication of the 
findings of this meta-analysis was sought in the African-American participants of the 
Candidate Gene Association Resource (CARe), which included the Cleveland Family Study 
(CFS), the Coronary Artery Risk Development in Young Adults (CARDIA) study, the 
Jackson Heart Study (JHS), and the Multi-Ethnic Study of Atherosclerosis (MESA) [33].
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Phenotype definition
Phenotype data were obtained from standardized personal interviews or self-completion 
questionnaires (Supplementary Table 1). The most widely available measure of sleep 
duration in the participating cohorts was self-report of usual hours of sleep at night; response 
options were typically whole number values. A smaller number of cohorts also collected 
self-reported usual bed and rise times, from which time in bed could be calculated. The 
relation between self-reported usual sleep duration and calculated time in bed was assessed 
in 9400 participants in the ARIC, CHS and FHS cohorts with data for both measures. 
Although the correlation between measures was fairly high at r=0.70, values differed by at 
least 1 hour in 24.3% of subjects and by at least two hours in 7.1% of subjects. Based on 
these differences, and for consistency on phenotype definition, calculated time in bed was 
not used as a proxy for self-reported usual sleep duration in meta-analyses.
Measures of sleep duration were also ascertained separately for weekday nights and 
weekend nights in some cohorts. In advance of performing genetic association testing, the 
heritability of weekday versus weekend sleep duration, assessed by the questions, “How 
many hours of sleep do you usually get at night (or your main sleep period) on weekdays or 
workdays?” and “How many hours of sleep do you usually get at night (or your main sleep 
period) on weekends or your non-workdays?” was explored in the Framingham Heart Study 
Offspring cohort, which includes many sibling pairs, using the program SOLAR [34]. Based 
on 2388 individuals in 726 sibships, the estimated heritability of age- and sex-adjusted usual 
sleep duration on weekday nights was 23.6% (SD 7.7%), somewhat lower than the 
previously reported heritability of sleep duration from twin studies [1–3], while for weekend 
nights heritability was estimated at only 12.3% (SD 7.2%). Therefore, where weekday and 
weekend night sleep duration were both available, weekday night sleep duration was 
analyzed. In order to exclude subjects in whom night shift work might lead to spurious 
estimates of sleep duration, subjects reporting a usual bedtime between 5 AM and 6 PM 
were excluded from analysis, where these data were known. Those whose usual sleep 
duration differed by more than two hours between weekdays and weekends were also 
excluded from analysis, where this difference was known, as behavioral factors were 
presumed to have a major influence on this measure.
Genotyping and association analysis
Genotyping arrays and cohort-specific quality control filters are provided in Supplementary 
Tables 2a and 2b. Allele dosage was imputed using the software indicated. Association 
testing was performed independently in each of the contributing cohorts, using an additive 
model and untransformed sleep duration, adjusted for age and sex, which are both strong 
predictors of sleep duration, plus any covariates used by the individual cohorts to account 
for likely sources of population stratification or for relatedness among subjects 
(Supplementary Table 3). A fixed-effects meta-analysis of the cohort-specific results was 
performed using the inverse variance-weighted method in METAL [35], with a total of 
2,033,301 single nucleotide polymorphisms (SNPs) tested. Genomic control correction was 
applied at the time of meta-analysis; individual cohort inflation factors ranged from 0.98 to 
1.05. Only SNPs with minor allele frequency >0.05 and without significant heterogeneity 
across cohorts at p<0.01 were considered. A threshold p<5 × 10−8 was specified for 
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statistical significance, corresponding to a Bonferroni correction for an estimated 1 million 
independent tests. All SNPs for the replication in African-Americans were present on the 
Affymetrix 6.0 SNP array used to genotype the CARe African-American sample, and were 
thus directly genotyped rather than imputed. Association analyses were adjusted for age, sex 
and the first 10 principal components to control for population stratification, and results of 
the four cohorts combined using fixed-effects meta-analysis in METAL. Conditional multi-
SNP association testing was performed using GWAS summary statistics, as previously 
described [36]. Power analyses were performed using Quanto v1.2 [37].
Evaluation of possible SNP function
Evidence that SNPs significantly associated with sleep duration, and those in linkage 
disequilibrium (LD) with these SNPs at r2 >0.5 in HapMap Utah residents with ancestry 
from northern and western Europe (CEU), as defined by SNP Annotation and Proxy Search 
(SNAP) queries [38], had an influence on gene expression was sought in the expression 
quantitative trait locus (eQTL) database of the Pritchard Lab (eqtl.uchicago.edu, accessed 
November 18, 2012) and in a separate query of significant results from >50 gene expression 
datasets covering multiple tissues (Supplementary Table 4). Evidence for an effect of SNPs 
of interest on thyroid function was sought through a lookup of results of the Meta-Thyroid 
consortium [39]. Cohorts in the consortium include several participating in the current 
analysis of sleep duration (CHS, FHS, HBCS, InCHIANTI, Rotterdam Study and UK 
Twins), as well as multiple additional cohorts. Data on glycemic traits were contributed by 
MAGIC investigators and downloaded from www.magicinvestigators.org. Data on Type 2 
diabetes mellitus were contributed by DIAGRAM investigators and downloaded from 
diagram-consortium.org. Data on psychiatric illnesses was obtained from published GWAS 
analyses of the Psychiatric Genomics Consortium (PGC), with data visualized using the 
Ricopili tool (http://www.broadinstitute.org/mpg/ricopili/) and downloaded from the PGC 
website (http://www.med.unc.edu/pgc/data-sharing#SharingOpp).
RESULTS
Cohort-specific genome-wide association analyses of self-reported usual sleep duration from 
18 population-based cohorts were meta-analyzed (Fig. 1). All included subjects from these 
discovery cohorts were European or of European descent (Table 1). No evidence of 
population stratification was noted in the meta-analysis of self-reported usual sleep duration 
(Supplementary Fig. 1; overall λ=1.06; the range of inflation factors for individual cohorts 
was 0.98 – 1.05). Two independent loci showed genome-wide significant association with 
usual sleep duration (Table 2, Fig. 2, and Fig. 3).
Identification and replication of a novel sleep duration locus on chromosome 2
The most strongly associated locus is located between two genes on chromosome 2: 30–80 
kb upstream from paired box gene 8 (PAX8) and, on the opposite strand, 80–130 kb 
upstream from cobalamin synthase W domain-containing protein 2 gene (CBWD) (Fig. 2). 
PAX8 is a well-characterized transcription factor essential to the formation of thyroxine-
producing follicular cells during thyroid development. PAX8 mutations produce thyroid 
dysgenesis, but the transcription factor is more widely expressed and may have other 
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functions. In contrast, CBWD2 is a poorly characterized gene highly expressed in the brain. 
The intergenic region also overlies a poorly characterized, predicted non-coding RNA 
(LOC101927400). This locus contains four SNPs meeting pre-specified criteria for genome-
wide significance: rs1191685 (p=1.1 × 10−9), rs1823125 (p=1.7 × 10−9), rs1807282 (p=3.9 
× 10−9), and rs1964463 (p=1.1 × 10−8), with minor allele frequencies of 0.25 to 0.37, that 
were associated with an increase in self-reported usual sleep duration of 2.8 (SE 0.5) to 3.0 
(SE 0.5) minutes per night per copy of the minor allele, explaining an estimated 0.07% of 
phenotypic heterogeneity. Linkage disequilibrium between the most strongly associated 
SNP and each of the other three significantly associated SNPs at this locus was modest, with 
r2 values between 0.51 and 0.64 in the HapMap 2 CEU sample. Conditional association 
testing was performed using summary-level statistics from the meta-analysis as previously 
described [36] with LD estimates derived from a representative sample of 4000 unrelated 
Australians of European descent. Conditioning on rs1191685, the effect sizes for the other 
SNPs reported above were reduced by approximately 60% and were no longer genome-wide 
significant (range of p values 0.003 to 0.01).
The direction of effect was positive in all but one cohort (Supplementary Fig. 2). Although 
there was no significant heterogeneity across cohorts, in 9 of the European-descent cohorts, 
the estimated effect was >5.0 minutes per night per copy of the minor allele, while in 8 of 
the cohorts the estimated effect was <2.6 minutes per night. The former cohorts were on 
average substantially older, with a mean age of 70 (SD 8) years, versus a mean age of 50 
(SD 12) years in the latter group, and there was a strong correlation between mean age of 
cohort participants and estimated effect size (r=0.72, p=0.001). Although most of the 
participating cohorts excluded related individuals, two were twin studies (QIMR, TwinsUK) 
and two were family studies (FHS, QFS). A sensitivity analysis excluding these cohorts 
from the meta-analysis found a somewhat stronger effect size for all four SNPs, with effect 
estimates of 3.3 to 3.7 minutes per night. The strongest association in this sample was at 
rs1807282 (p=2.4 × 10−10).
Three of the significantly associated SNPs in this region were directly genotyped in the 
Candidate-gene Association Resource (CARe) [33] African-American sample (rs1823125, 
rs1807282, rs1964463); a fourth directly genotyped SNP (rs1191684) was in perfect linkage 
disequilibrium with rs1191685 in the HapMap 2 Yoruba in Ibadan, Nigeria (YRI) sample. 
Interestingly, these four SNPs have very little linkage disequilibrium in the HapMap 2 YRI 
sample, with r2 values of 0.001 to 0.04 (Supplementary Fig. 3). Association testing in this 
sample of 4771 individuals replicated the finding from the discovery cohorts (Table 3), with 
effect sizes in the African-American sample that were in the same direction and somewhat 
larger than those seen in the discovery sample in three of the four SNPs, with 2 out of 4 
SNPs reaching significance in the replication sample after Bonferroni correction. The 
strongest association in African-Americans was at rs1807282, with an effect size 11.2 (SE 
3.4) minutes per night per copy of the minor allele (p=9.34 × 10−4), explaining 0.15% of 
phenotypic variance in this sample. When meta-analyzed together, the strongest association 
was with SNP rs1823125, the minor allele of which was associated with a sleep duration 3.1 
minutes per night longer (p=1.47 × 10−10, Table 3).
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The locus of significant association is in the vicinity of an enhancer that is associated with 
an in vitro increase in PAX8 gene expression of up to 250-fold [40]. None of the SNPs that 
were significantly associated with sleep duration are associated with significant differential 
expression of PAX8 in published gene expression databases; no thyroid tissue gene 
expression databases are available, however. A lookup of these SNPs in the Meta-Thyroid 
consortium analysis of over 20,000 individuals of European ancestry [39] found no evidence 
for association of any of these SNPs with blood levels of either thyroid stimulating hormone 
or free thyroxine. The SNP rs1191685 is significantly associated with differential expression 
in skin of a transcript of IL1RN (p=3.30 × 10−5), which encodes the interleukin-1 receptor 
antagonist [41]. This eQTL signal peaks at rs1191683, which is in high LD with rs1191685 
(r2=0.80); a signal was not seen in a smaller skin eQTL dataset [42]. Because of a strong 
association of short sleep duration with diabetes mellitus and other glycemic traits [43], we 
performed a look-up of these SNPs in published GWAS analyses of these traits. Three of the 
SNPs (rs1807282, rs1823125, rs1964463) showed nominally significant association with the 
homeostatic model assessment of beta cell function (HOMA-β, p=0.04, [44]) and with 
glycated hemoglobin (HgbA1C, p=0.008 to 0.011, [45]). In each case, the minor allele, 
which is associated with longer sleep duration, is associated with a more favorable 
metabolic profile, i.e., higher HOMA-β and lower HgbA1C. No association of these SNPs 
with Type 2 diabetes mellitus was present in data from the DIAGRAM consortium 
(DIAGRAMv3.2012DEC17). Because sleep disturbance is a common symptom in a number 
of psychiatric illnesses, we also performed a lookup of these SNPs in published PGC GWAS 
analyses. Attention deficit hyperactivity disorder (ADHD) was associated with SNPs 
rs1823125, rs1807282, and rs1964463 (p=0.03 for each) [46]. In each case, the allele that 
was that associated with longer usual sleep duration in the present study was associated with 
a lower ADHD risk in the PGC analysis. No significant association of these SNPs, or any in 
LD with these SNPs at r2 >0.4, was present for schizophrenia, depression or bipolar 
disorder. The association of ADHD has two local peaks, at rs1191694 and rs13032628 (each 
p=0.004), which are in very low LD with one another (r2=0.07). The sleep duration-
associated SNPs rs1823125 and rs1807282 are approximately 5600 and 2800 bp, 
respectively, from these ADHD-associated SNPs (r2=0.12–0.13 for LD between sleep 
duration-associated SNPs and rs1191694; r2=0.06 for LD between sleep duration-associated 
SNPs and rs13032628).
Identification of a second novel sleep duration locus on chromosome 6
The second region of genome-wide significant association in the cohorts of European 
descent is located on chromosome 6 in an intergenic region approximately 50 kb upstream 
of IER3 and FLOT1 (Fig. 3), which also contains a long intergenic non-coding RNA 
(LINC00243) of uncertain function. The three SNPs with genome-wide significant 
association span only 924 bp and are in perfect linkage disequilibrium in both the CEU and 
YRI samples. In the discovery cohorts, the minor allele frequency was 0.20 and the strongest 
estimated association with sleep duration was 3.1 (SE 0.6) minutes less sleep per night per 
copy of the minor allele, explaining 0.07% of phenotypic heterogeneity. These SNPs are 
also in perfect linkage disequilibrium with two SNPs (rs4713380 and rs4713385) that are 
significantly associated with the expression in peripheral whole blood of transcripts of the 
genes IER3 (p=8.40 × 10−23), FLOT1 (p=4.00 × 10−17), VARS2 (p=4.60 × 10−12) and TUBB 
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(p=4.20 × 10−5) [47], and in both skin (p=1.60 × 10−9) and B-lymphoblastoid cell lines 
(p=6.49 × 10−5) with expression of IER3 [41]. A lookup in the PGC cross-disorder GWAS, 
which analyzed the association of genotype jointly with five psychiatric disorders (ADHD, 
autism spectrum disorders, bipolar disorder, major depressive disorder and schizophrenia), 
indicated that the three SNPs on chromosome 6 that are associated with sleep duration are 
significantly associated with psychiatric disorders (p=0.0003 to 0.001) [48]. These SNPs are 
part of a LD block spanning approximately 30,000 bp, and are in complete LD (r2=1.0) with 
10 additional SNPs in this block, each of which is associated with the psychiatric disorders 
at p=4.7–9.9 × 10−5. This association was driven by associations with major depressive 
disorder (p=0.02 to 0.05) [49] and schizophrenia (p=0.04 to 0.08) [50]. In each case, the 
allele associated with shorter sleep duration in the present analysis was associated with 
increased depression and schizophrenia risk in the PGC analyses. Notwithstanding these 
suggestive correlates, this region did not replicate in the African-American sample. The 
effect was in the same direction but somewhat smaller (2.2 – 2.6 minutes less sleep per night 
per copy of the minor allele), and not statistically significant (lowest p=0.39), although 
given a MAF of 0.09–0.10, the power to detect a significant replication of an effect of the 
magnitude seen in the discovery sample was low (range 17–18%).
Additional novel sleep duration loci and evaluation of candidate genes
An additional 11 loci were associated with usual sleep duration in the GWAS of the 
discovery cohorts at a nominal p <10−5 (Table 4); none was significantly associated with 
sleep duration in the replication cohort, albeit with low power to detect significant effects 
(power <30% for each locus). A number of genes have been associated with sleep duration 
or chronotype through smaller candidate gene or GWAS studies that had no overlap with the 
cohorts included in the present study. The present GWAS included multiple SNPs in these 
genes and other core mammalian clock genes, including ABCC9 (131 SNPs), PER2 (22 
SNPs), PER3 (56 SNPs), CLOCK (110 SNPs), ARNTL (114 SNPs), ARNTL2 (106 SNPs), 
and CSNK1D (6 SNPs). No SNPs in BHLHE41 were present in the GWAS. There was no 
evidence for association at any of these SNPs with usual sleep duration, using a liberal 
threshold of p<0.01. The SNP rs12649507 in CLOCK, previously reported to be associated 
with usual sleep duration with an effect size of approximately 5 minutes shorter sleep per 
night in homozygotes for the minor allele than in homozygotes for the major allele [8], had a 
smaller estimated effect in the present study of 0.9 minutes shorter sleep per night per copy 
of the minor allele (p=0.03). The SNP rs11046205 in ABCC9, previously reported to be 
associated with usual sleep duration with an effect size of approximately 10 minutes longer 
sleep per night per copy of the minor allele [11], had an estimated effect in the present 
analysis of only 0.9 minutes longer sleep per night per copy of the minor allele (p=0.11).
DISCUSSION
This genome-wide association study identified two loci with genome-wide significant age- 
and sex-adjusted association to self-reported usual sleep duration in a large, multi-national 
sample of adults from Europe or of European descent. One of these loci was replicated in a 
sample of African-Americans, strengthening the finding. This first locus is located 
approximately 30–80 kb upstream from the thyroid-specific transcription factor PAX8 and, 
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at a somewhat greater distance, upstream from CBWD2. It also overlies a predicted non-
coding RNA LOC101927400 and is approximately 200 kb from an interleukin-1 gene 
cluster. While little is known about the function of CBWD2, PAX8 is a transcription factor 
that is most highly expressed in thyroid tissue, where it is important both in thyroid 
development and in maintaining adult thyroid function [51]. Thyroid-stimulating hormone 
levels are reduced by sleep deprivation [52, 53], with both higher [52] and lower [53] free 
thyroxine levels reported. Hypothyroidism is associated with excessive sleepiness [54] and 
with reductions in slow-wave sleep that can be corrected with hormone replacement [55], 
while hyperthyroidism is associated with insomnia [56]. These findings suggest a role for 
thyroid hormone in sleep-wake regulation and thus a plausible role for PAX8 effects on 
sleep duration. The locus of interest is in the vicinity of an enhancer that is associated with 
an in vitro increase in PAX8 gene expression of up to 250-fold [40]. As no thyroid-specific 
eQTL databases are available, and PAX8 is expressed in adults primarily in the thyroid 
gland, it was not possible to assess whether these variants are associated with changes in 
PAX8 expression; however, these SNPs were not associated with measures of thyroid 
function in a genome-wide association study, albeit in a smaller sample [39]. An alternative 
possibility is suggested by the association of rs1191685 with expression of IL1RN, as its 
product, the interleukin-1 receptor antagonist, has been shown to block the somnogenic 
effect of interleukin-1 [57], which is hypothesized to be involved in the physiologic 
regulation of sleep. The IL1RN is located 100 kb downstream of PAX8 and a regulatory 
element for this receptor could be distantly located between PAX8 and CBWD2 (Fig.1). 
Although the mechanisms discussed above remain speculative, the cross-racial replication of 
the association suggests a true effect of this locus on usual sleep duration.
While the magnitude of the association of the SNPs upstream of PAX8 with sleep duration 
appears modest, with each copy of the minor allele associated with an estimated increase in 
usual sleep duration of approximately 3 minutes per night, the 0.07% of variance in sleep 
duration explained by this variant is typical of GWAS studies. For example, of 32 loci 
showing genome-wide significant association with body mass index in the GIANT 
Consortium analysis of almost 250 000 individuals, only four explained greater than 0.07% 
of the variance in body mass index, with the two most strongly associated loci (FTO and 
TMEM18) explaining 0.34% and 0.15% of variance, respectively, and the remaining 30 
variants explaining an average of 0.03% of variance each [58]. Moreover, self-reported 
usual sleep duration is likely to be an imprecise correlate of the underlying biological 
construct of interest, which is the innate sleep period of the individual free of environmental 
constraints. This reflects both technical factors, including imprecision in self-report 
estimates of sleep duration compared to objective measures such as actigraphy [59] and the 
coarse-grained response options typical of sleep duration questionnaires, as well as 
extensive socio-environmental influences on sleep behaviors, including the widespread 
consumption of caffeine and alcohol, the impact of medical and psychiatric illness on sleep, 
and most importantly the impact of work and social schedules that are often unrelated to 
individual differences in optimal sleep duration. In older individuals, retirement from work 
and lack of childrearing responsibility often reduce the impact of social demands on sleep 
schedule, perhaps explaining the stronger effect observed in the older cohorts included in 
this analysis.
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Although the present study is more than 10-fold larger than the two previously published 
GWAS studies of sleep duration, it remains small compared to recent studies of traits such 
as body mass index and hypertension, which are more widely available in large population-
based cohorts. The replicated locus upstream from PAX8 is therefore likely to represent the 
first of a larger number of associations that will appear as future population-based GWAS 
studies of sleep duration benefit from more rigorous phenotyping and larger sample size. 
Self-reported short sleep duration and experimental sleep restriction are strongly associated 
with impaired glucose metabolism [43]. Sleep disturbance and short sleep duration are also 
common in psychiatric disorders, including ADHD. It is therefore of interest that the alleles 
upstream from PAX8 that are associated with longer sleep duration in this study were in 
prior GWAS studies associated with higher HOMA-β and lower HgbA1C [44,45] and with 
lower ADHD risk [46]. As sleep duration is associated with other important illnesses, 
including incident post-traumatic stress disorder [60], obesity, hypertension, and coronary 
heart disease, as well as with mortality, elucidating the molecular pathways that regulate 
sleep duration may both identify novel mechanisms affecting sleep regulation and help to 
explain its association with psychiatric and cardiometabolic disease.
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Figure 1. 
Manhattan plot for genome-wide association with usual sleep duration in cohorts of 
European descent.
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Figure 2. 
Chromosome 2 regional association plot for usual sleep duration in cohorts of European 
descent. Figure was constructed using the Broad Institute SNAP tool (http://
www.broadinstitute.org/mpg/snap/).
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Figure 3. 
Chromosome 6 regional association plot for usual sleep duration in cohorts of European 
descent. Figure was constructed using the Broad Institute SNAP tool (http://
www.broadinstitute.org/mpg/snap/).
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